Granules India Ltd (GRANULES)
₹839.75
Mkt cap
₹22,907 Cr
P/E ratio
35.20
P/B
4.10
Div yield
0.21%
ROE
13.80%
ROCE
15.50%
EPS (TTM)
₹23.86
Book value
₹205
52W range
530–924
Sector
Healthcare
Price history
Previous close
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages. [1]
NSE GRANULESBSE 532482
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−9.08% from high₹840
₹530+58.49% from low₹924
Current
₹839.75
Prev close
₹837.35
Day
+0.29%
Price performance
1D
+0.20%
1W
+5.57%
1M
−3.20%
3M
+0.61%
6M
+19.08%
1Y
+50.59%
YTD
+36.47%
Financials
Revenue, profit & margin
P/E ratio
35.2×
GRANULES is 2% above the sector median of 34.4×
GRANULES35.2×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 986 | 1,189 | 1,156 | 1,176 | 1,180 | 967 | 1,138 | 1,197 | 1,210 | 1,297 | 1,388 | 1,471 | 1,477 | |
| Expenses | 849 | 977 | 905 | 920 | 921 | 763 | 907 | 945 | 963 | 1,019 | 1,080 | 1,119 | 1,138 | |
| Operating Profit | 137 | 213 | 250 | 256 | 259 | 203 | 230 | 252 | 247 | 278 | 308 | 352 | 339 | |
| OPM % | 14% | 18% | 22% | 22% | 22% | 21% | 20% | 21% | 20% | 21% | 22% | 24% | 23% | |
| Other Income | 0 | 2 | 1 | 2 | 2 | 3 | 6 | 33 | -10 | -1 | -4 | 25 | 2 | |
| Interest | 22 | 26 | 29 | 29 | 27 | 26 | 27 | 24 | 24 | 29 | 29 | 33 | 21 | |
| Depreciation | 49 | 53 | 52 | 53 | 53 | 53 | 57 | 64 | 69 | 72 | 74 | 82 | 80 | |
| Profit before tax | 65 | 136 | 170 | 176 | 181 | 128 | 153 | 198 | 145 | 176 | 202 | 262 | 240 | |
| Tax % | 27% | 25% | 26% | 26% | 26% | 24% | 23% | 23% | 22% | 26% | 26% | 23% | 25% | |
| Net Profit | 48 | 102 | 126 | 130 | 135 | 97 | 118 | 152 | 113 | 131 | 150 | 202 | 180 | |
| EPS in Rs | 1.98 | 4.21 | 5.18 | 5.35 | 5.56 | 4.01 | 4.85 | 6.27 | 4.64 | 5.38 | 6.19 | 8.13 | 7.26 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
2 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.52% · closed higher next day 21 of last 58
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23◦ | 23 Jan '24 | 15 May '24◦ | 30 Jul '24 | 6 Nov '24◦ | 24 Jan '25 | 28 May '25 | 12 Aug '25 | 13 Nov '25 | 23 Jan '26◦ | 29 Apr '26 | 21 Jul '26 |
| Earnings day | −0.96% | −1.09% | +0.79% | +4.27% | −0.75% | −2.94% | −1.21% | +3.30% | +2.55% | +2.50% | −0.09% | −0.05% |
| +1 day | −0.31% | +0.13% | +1.30% | +11.55% | +1.40% | −9.17% | +1.23% | +4.49% | +1.06% | −0.02% | −0.77% | −2.55% |
| +5 days | −0.80% | −0.18% | +8.23% | +14.90% | −7.38% | −7.21% | −0.27% | +4.72% | +1.54% | +1.20% | +5.44% | −3.50% |
| +15 days | +5.13% | +3.70% | +18.02% | +22.97% | +3.23% | −9.56% | −6.41% | +16.41% | +4.42% | +0.67% | +8.37% | −1.72% |
| +30 days | +7.39% | +10.09% | +24.19% | +19.80% | +1.78% | −17.75% | −9.31% | +20.34% | +13.81% | +3.75% | +8.69% | −4.44% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 1.75 Per Share | 1.75 | 30 Jul '26 | 30 Jul '26 |
Shareholding
as of Sep 202637.39%Promoter
Promoters37.39%0.62
FIIs20.25%2.75
DIIs15.33%0.78
Public27.04%1.32
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Granules India | ₹839.75 | 35.23 | 22,907 | 0.21% | 180 | +36.62% | 1,477 | +22.04% | 15.51% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts89
TranscriptOct 2026RECOct 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026PPTApr 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptJan 2025PPTJan 2025TranscriptNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Oct - Gagillapur facility received FDA 483 with 11 observations after Oct. 19-30 inspection; no manufacturing impact.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Oct - Granules India schedules Q2 and H1 FY27 earnings call on November 2, 2026 at 6:00 PM IST.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 24 OctDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 24 Oct - Promoter group received 2.49 crore shares on warrant conversion; holding rose to 37.39% on 16 Sep 2026.Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 24 Oct - Revised SEBI disclosure: Dr Krishna Prasad Chigurupati sold 1.72 crore Granules India shares on 11 September 2026.